Followers | 827 |
Posts | 119535 |
Boards Moderated | 15 |
Alias Born | 09/05/2002 |
Tuesday, May 02, 2017 12:10:14 PM
• Possibility of 40mg-Glatopa approval before year-end is perhaps larger than investors thought after NVS took 40mg Glatopa out of 2017 guidance on its own 1Q17 CC.
• MNTA claims to have a commercialization path for M834 (Orencia) despite losing the recent IPR on BMY’s sub-Q-formulation patent.
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
FEATURED NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM